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ATP Adenosine triphosphate 
BCL-2 B-cell lymphoma 2 
CCRL2 C-C chemokine receptor-like 2 
CD Cluster of differentiation 
CLRs C-type Lectin Receptors 
CMKLR1 Chemokine-like receptor 1 
COX Cyclooxygenase 
CRT calreticulin 
CT Computed tomography 
CyH Cyclosporin H 
DAMPs Damage-associated molecular patterns 
DCs Dendritic cells 
DNA Deoxyribonucleic acid 
ERK Extracellular signal–regulated kinases 
FITC Fluorescein isothiocyanate 
fMLP N-formylmethionine-leucyl-phenylalanine 
fNLPNTL N-formyl-norleucyl-leucyl-phenylalanyl-norleucyl-tryrosyl-lysine 
FPR1 Formyl-peptide receptor 1 
GPCRs G-protein coupled receptors 
GPR1 G protein-coupled receptor 1 
HIF-1α Hypoxia-inducible factor 1α 
HIV Human immunodeficiency virus 
HMGB1 High-mobility group box 1 protein 
HSP Heat shock proteins 
iDCs Immature dendritic cells 
IFN-γ Interferon gamma 
IL Interleukin 
JNK C-Jun N-terminal protein kinases 
kDa Kilodalton 
LSECs Liver sinusoidal endothelial cells 
MAPK Mitogen-activated protein kinase 
MCL-1 Myeloid cell leukemia 1 























MRI Magnetic resonance imaging 
mTOR Mammalian ( mechanistic) target of rapamycin 
MYCN N-myc proto-oncogene protein 
NB Neuroblastoma 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NK Natural killer cell 
NLRs NOD-like receptors 
NSAIDs Nonsteroidal anti-inflammatory drugs 
PAMPs Pathogen-associated molecular patterns 
PCR Polymerase chain reaction 
PI3K Phosphoinositide 3-kinase 
PRRs Pattern recognition receptors 
PTEN Phosphatase and tensin homolog deleted on chromosome 10 
RLRs RIG-I-like receptors 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
shRNA Short (small) hairpin RNA 
siRNA Small interfering RNA 
STAT3 Signal transducer and activator of transcription 3 
TAMs Tumor-associated macrophages 
TGF-β Transforming growth factor beta 
TLRs Toll-like Receptors 
TNF-α Tumor necrosis factor alpha 
Tregs Regulatory T cells 
VEGF Vascular endothelial growth factor 
WB Western blot 




3.1  Cancer and inflammation 
The theory about the interplay between inflammation and cancer was suggested by Rudolf Virchow 
at the end of the 19th century when he observed the presence of immune cells in tumor samples. 
Virchow supposed that persistent inflammation induces a malignant transformation of the tissues [1]. 
More than a century later, in 2011, a tumor-promoting inflammation was included as an enabling 
characteristic in the monumental work of Hanahan and Weinberg “Hallmarks of Cancer: The Next 
Generation” [2]. Inflammation contributes to tumor angiogenesis, invasiveness and metastatic 
activity by augmentation of the proliferation and inhibition of death signaling in cancer cells (Figure 
1).  
In short, the inflammatory process occurs in a tissue as a response to an injury, and its main role is to 
heal the tissue. Tissue-residing immune cells expressing specific pattern recognition receptors 
(PRRs), which recognize antigens or danger signals released by damaged cells, produce inflammatory 
mediators that form a focus of inflammation and induce the migration of various leukocytes from the 
vessels to the site of the damage. During the sequence of processes, immune cells in cooperation with 
extracellular matrix forming cells (fibroblasts) eliminate the source of danger signals and resolve the 
inflammation. In the case of a “normal inflammation”, associated with wound healing, these 
processes are limited and securely controlled by various growth factors including interleukins, TNF-
α and TGF-β [3-6]. A loss of regulation in inflammation limiting factors leads to the persistence of 
focus, and may result in neoplastic formation 
Generally speaking, the most potent drivers of the chronic inflammatory process associated with 
cancer are the sustained presence of inflammatory immune cells and the subversion of inflammatory 
mediators’ production. 
The typical cells promoting cancer-related inflammation are tumor-associated macrophages (TAMs) 
[7, 8]. Depending on the type of polarization, TAMs may play different roles in inflammation. M1 
(classical) phenotype macrophages eliminate antigens and cancer cells by the production of IL-12, 
IL-23, TNF-α and the recruitment of cytotoxic T cells and NK cells. M2 (alternative) phenotype 
macrophages produce IL-6, IL-10 and TGF-β, thereby resulting in an immune-suppressed response. 







Figure 1. Cancer-related inflammation. There are two pathways driving cancer-related inflammation: the 
intrinsic pathway and the extrinsic pathway. The intrinsic pathway is activated by genetic events that cause 
neoplasia including the activation of oncogenes, chromosomal aberrations, and the inactivation of tumor-
suppressor genes. The extrinsic pathway is driven by inflammatory conditions that predispose to cancer. Together 
these pathways activate NF-κB, STAT3, and HIF-1α in tumour cells. These transcription factors initiate the 
production of inflammatory mediators, including cytokines and chemokines, as well as the production of COX-2. 
These factors recruit various leukocytes. All these events lead to an augmented production of inflammatory 
mediators and improved generation of cancer microenvironment.  
Illustration used with permission, copyright 2016 by the American Thoracic Society (ATS) [16]. 
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Tumor-promoting immune cells are not limited by TAMs, as recent data show that dendritic cells, 
neutrophils, mast cells and T cells may also contribute to tumor development, releasing chemokines, 
immunosuppressive cytokines, pro-angiogenic components, ROS and proteases [17-24]. 
Additional evidence of the significance of inflammation in cancer progression is clearly demonstrated 
by studies which show that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces 
colorectal [25], lung [26, 27], breast [28, 29], esophagus [30] and stomach [31] cancer risks. The 
chemopreventive properties of NSAIDs can be explained by their ability to inhibit cyclooxygenases 
(COX-1 and -2), while COX-2 stimulates the production of prostaglandins from arachidonic acid 
[32]. In turn, prostaglandins promote tumor development by apoptosis inhibition, immune 
suppression, the stimulation of cell proliferation and the activation of pro-survival signaling pathways 
[33-35]. 
 
3.2.1 Pattern recognition receptors and danger signals 
The initial discovery of the immune system originated in the BC era. However, the underlying 
intricate mechanisms of the immune response remained unclear up until the end of the 20th century. 
In 1989, Charles A. Janeway, Jr. proposed the pattern recognition concept that revolutionized the 
field of immunology [36]. Janeway postulated that the initiation of the immune response relies on the 
set of highly conserved receptors called pattern recognition receptors (PRRs) which recognize 
specific ligands of microbial origin (e.g. components  of the bacterial cell wall, bacterial and viral 
nucleic acids, etc.) called pathogen-associated molecular patterns (PAMPs). Janeway also 
emphasized that besides the activation of the innate immunity, PRR-PAMP interactions trigger the 
adaptive response. 
First PRR was described in the middle of the 1990s in a Drosophila model. Lemaitre and co-authors 
showed that flies with the mutant Toll transmembrane protein lack the antifungal immune response 
[37]. Further research revealed a number of additional Toll-related proteins and in 1997 Medzhitov 
and co-authors characterized a human homologue of the Drosophila Toll protein [38]. At present, the 
PRR superfamily consists of a wide variety of receptors with diverse chemical structures and 
signaling mechanisms. Among different species, approximately 500 PRRs are currently known [39]. 
In order to pursue the permanent immune control, PRRs are extensively distributed throughout the 
body. PRRs can reside in cell membranes (Toll-like receptors, C-type lectin receptors) and cytoplasm 
(RIG-I-like receptors, NOD-like receptors), or they can be secreted (complement system proteins, 
pentraxins) (Figure 2). An interaction between PRR and ligands results in the initiation of different 
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signaling pathways, including NF-κB [40, 41], JNKs [42] and p38 [43], thus leading to the 
inflammasome formation and production of pro-inflammatory cytokines and interferons. [44] 
For a long time, the dogma that the immune system distinguishes between the “self” and “non-self” 
has dominated the field, though in 1994, Polly Matzinger outlined a theory which seemed to 
contradict all existing immunology principles [45]. She suggested that the immune response is 
promoted by so-called “danger signals” (later termed damage-associated molecular patterns - 
DAMPs), i.e. host-derived substances released by the cells in response to stress, damage, etc. Despite 
Figure 2. Localization of main classes of PRRs. PRRs can be localized on the cell surface, in the cytoplasm 
and in the membrane of endosomes. 




the controversy, this theory could explain phenomena that previous thoughts have failed to 
understand.  
DAMPs are structurally diverse immunostimulatory molecules that can be released from any 
compartment of the cell following tissue damage, trauma, inflammation and neoplastic changes. 
There are several ways to classify DAMPs: 
1. Release mechanism 
a. Actively released (calreticulin (CRT), adenosine triphosphate (ATP)) [46] 
b. Passively released (high-mobility group box 1 protein (HMGB1), s100 proteins, etc.) [47] 
2. Source 
a. Intracellular DAMPs (mitochondrial formylated peptides, including fMLP; nuclear 
HMGB1; s100 proteins) [47, 48] 
b. Exosomal DAMPs (heat shock proteins (HSP)) [49] 
c. Extracellular matrix DAMPs (hyaluronic acid) [50] 
d. Plasma components (complement proteins C3a, C4a, C5a) [51] 
3. Chemical structure 
a. Proteins (HMGB1, HSP, etc.) [50] 
b. Non-proteins (free nucleic acids, ATP, heparan sulfate, etc.) [50, 52, 53] 
 
Released extracellularly, DAMPs bind to PRRs and exhibit their properties including the stimulation 
and regulation of dendritic cells (DCs) maturation, which lead to the induction of CD8+ T-cell 
response [54]. 
Over the last few decades, it has become apparent that the PRR concept and danger theory are not 
mutually exclusive, but instead complementary. PRRs work not only as a primitive bacterial 
recognition machinery, but can also initiate an immune response activated by both foreign antigens 
(PAMPs) and host substances (DAMPs). 
 
3.2.2 Formyl peptide receptor 1 (FPR1) 
The human formyl peptide receptor 1 (FPR1) is a seven transmembrane domain receptor that belongs 
to the superfamily of G-protein coupled receptors (GPCRs) (Figure 3) [55]. It is expressed at high 
levels on phagocytic leukocytes, and mediates cellular chemotaxis [56]. Human FPR was identified 
in the late 1970s on the surface of neutrophils as a specific receptor for bacterial N-formyl peptide 
formyl-methionine-leucyl-phenylalanine (fMLP) [57, 58]. It has later been shown that the activation 
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of FPR1 by picomolar and nanomolar concentrations of fMLP promotes chemotactic cell motility 
and the mobilization of intracellular Ca2+ [59, 60] 
Upon binding with an agonist, FPR1 activates heterotrimeric Gi protein, which dissociates into α and 
βγ subunits, with the subsequent activation of phospholipase C (PLC) and phosphoinositide 3-kinase 
(PI3K). PLC hydrolyzes phosphatidylinositol 4,5-biphosphate (PIP2), resulting in the generation of 
inositol trisphosphate (IP3), which leads to the release of calcium from endoplasmic reticulum and 
the activation of protein kinase C isoforms [61-63]. Main intracellular pathways activated by FPR1 
are PI3K/Akt, MAPK, STAT3, p38 and Hippo pathways [56, 64-66]. All these intracellular events 
lead to an increased chemotactic behavior of cells and the development of pro-inflammatory effects. 
It is known that different types and concentrations of an agonist activate different signaling pathways. 
As with other GPCRs, FPR1 is subject to homologous desensitization. In the presence of high 
concentrations of agonists, FPR1 can be internalized and kept in endosomes during long-term agonist 
exposure, without any signs of degradation [67]. 
Figure 3. Transmembrane disposition of the human FPR1. One-letter amino acid code is used. 
Illustration used with permission, copyright 2009 by The American Society for Pharmacology and 




Due to extensive research, the current list of known agonists for FPR1 is significantly broadened. 
Besides the classic fMLP, it includes: 
1. Peptides of bacterial and viral origin: a non-formylated peptide fragment produced by 
Helicobacter pylori, Hp(2–20); T20, T21 peptides of HIV-1 envelope protein gp41 [68-70] 
 
2. Ligands of endogenous origin: formylated peptides of mitochondria proteins fMMYALF, 
fMLKLIV and fMFADRW; peptides  Ac1-26 and Ac9-25 of Annexin I,  a Ca2+-dependent 
phospholipid binding protein [60, 71] 
 
3. Synthetic peptide library derived agonists: WKYMVm, WKGMVm, WKRMVm [72, 73] 
 
First selective antagonists for FPR1, t-Boc-Met-Leu-Phe (Boc1) and t-Boc-Phe-D-Leu-Phe-DLeu-
Phe (Boc2) were synthesized by replacing the formyl group of fMLF with the tertiary 
butyloxycarbonyl group (t-Boc) [74]. Fungal cyclic peptide Cyclosporin H (CyH), bile acids 
deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) are known FPR1 antagonists [75-78]. 
Although FPR1 was initially discovered in phagocytic leukocytes, it is widely expressed in other cell 
types and tissues including dendritic cells, endothelial cells, astrocytes, lens epithelial cells, 











Cell types Tissues 
Monocytes/macrophages Thyroid 
Neutrophils Adrenal 
Immature DCs Central nervous system 




Microglial cells Heart 
Fibroblasts Uterus 
Vascular smooth muscle cells Ovary 




 Bone marrow 
 Colon 
Table 1. Distribution of FPR1 in cells and tissues. Modified from [79]. Table used with permission, 




Accumulating data suggest that FPR1 is involved in a range of diseases and pathologic conditions, 
such as chronic obstructive pulmonary disease (COPD) [80], inflammatory colitis [81], periodontitis 
[82, 83] and several cancer types, including gastric cancer [84, 85], astrocytoma [86], melanoma [87], 
glioblastoma [61, 88], lung alveolar carcinoma [89], hepatocellular carcinoma [90], breast cancer [91] 
and pancreatic carcinoma [92]. 
3.3.1 Chemokines 
Chemokines are a family of small (8-14 kDa) chemotactic cytokines that induce directed migration 
of leukocytes. Based on the position of the primary cysteine residues near the N-terminus of these 
proteins, they are classified into four main subfamilies: C, CC, CXC and CX3C [93]. Chemokines 
exert their functions by binding to corresponding G-protein coupled receptors on target cells [94]. 
This binding activates various downstream signals including PTEN/PI3K/Akt, Jak-STAT and 
MAPK/ERK pathways, hence leading to increased cell motility and proliferation [95-97]. 
Additionally, chemokines can bind to proteoglycans and glycosaminoglycans. This ability allows 
them to accumulate on the surface of endothelial cells, or in an extracellular matrix and form a 
concentration gradient important in migration [98]. 
According to their functions, chemokines can be classified as inflammatory and homeostatic. The 
former induce the migration of immune cells to the site of inflammation, while the latter are involved 
in various stages of organogenesis, stem cell migration and the maintenance of natural leukocyte 
balance [99, 100].  
All immune cells express chemokine receptors, and their migratory potential is dependent on 
chemokines. In general, C chemokines are necessary for T cell migration to the thymus; CC 
chemokines promote the chemotaxis of basophils, DCs, macrophages, monocytes, NK cells, T cells, 
etc.; CXC chemokines attract B- and T- lymphocytes, neutrophils; CX3C chemokines are involved 
in T cell and NK cell infiltration [93, 101]. 
Chemokines have been shown to play an essential role in all stages of tumor development. Cancer 
cells both produce various chemokines and express chemokine receptors. For example, the tumor-
derived chemokines CCL2 and CCL22 recruit TAMs (and intensify their M2 polarizaion) and Tregs 
[102-104]; CXCL12 and CXCL8 upregulate VEGF expression, thus leading to neovascularization 
[105, 106]; CXCR4 expressed on the cancer cells initiate the migration towards its ligand CXCL12 






Chemerin (tazarotene induced gene 2, TIG2; retinoic acid receptor responder 2, RARRES2) is an 18 
kDa chemokine-like protein [110]. It is synthesized as a 163-amino acid inactive isoform that is 
cleaved to 143-amino acid prochemerin and subsequently processed by a variety of extracellular 
inflammation-associated proteases, which remove a C-terminal hexapeptide to liberate the 157- and 
156- amino acid active forms or 154- and 155- inactive forms [111]. First, it was described as a protein 




Structurally, chemerin is distinct from chemokines, but in binding its receptors, chemerin acts in a 
chemokine-like manner, inducing leukocyte chemotaxis (particularly macrophages, NK cells, DCs) 
and the mobilization of intracellular Ca2+ [114, 115]. There are three chemerin receptors described so 
far: chemokine-like receptor 1 (CMKLR1 or chemR23), chemokine CC motif receptor-like 2 
(CCRL2) and G protein-coupled receptor 1 (GPR1) (Figure 4). While CMKLR1 promotes the main 
chemoattractive functions of chemerin, the consequences of binding chemerin to GPR1 are not clearly 
understood. Interestingly, the CCRL2-chemerin complex does not undergo internalization, and it is 
believed that the main function of CCRL2 is to concentrate chemerin locally in order to present it to 
chemR23 more abundantly [110, 111, 114, 115]. There is some evidence demonstrating an 
Figure 4. Overview of the three receptors for chemerin. 




association between chemerin-induced inflammation and cancer (prostate cancer, esophageal cancer, 
gastric cancer, etc.) [116-118]. 
3.4  Neuroblastoma 
Neuroblastoma (NB) is an embryonal tumor of the peripheral nervous system and is the most common 
and deadly extracranial tumor of the childhood [119]. NB arises from sympathetic ganglia precursor 
cells developing from the neural crest, a transient embryonal population of cells that gives rise to the 
central nervous system, melanocytes, neuroendocrine cells, facial cartilage, etc [120]. 
The median age at diagnosis is 17-18 months [121, 122]. It has been shown that NB is slightly more 
common among boys than among girls [123] with the global incidence of NB being approxmately 1 
case per 8,000 – 10,000 births [122]. In the Norwegian population, the incidence is equal to 0.92 
cases per 100,000 (Wesenberg F, Monge O, Nygård JF, Lie HK, Småstuen M. Årsrapport 2009 Norsk 
Barnekreftregister). Survival in NB depends on the age of diagnosis and the genetic profile of the 
disease, but the overall survival is approximately 55% [124]. 
Anatomically, NB can arise at any part of the sympathetic nervous system, but it predominantly 
occurs in the adrenal medulla. Clinical manifestation of NB depends on the location of primary tumor. 
The most common sites of NB metastasis are regional lymph nodes, bones and bone marrow and the 
liver (Figure 5) [125]. The diagnosis is established by histological findings from tumors or metastases 
biopsies, various imaging techniques (CT, MRI, MIBG) and biochemical analysis of blood and urine 
(elevated levels of catecholamines and their metabolites are frequently presented) [119].  
The causes of NB are not known but two germline mutations in PHOX2B (paired-like homeobox 2b) 
and ALK (anaplastic lymphoma kinase) genes have been described to be involved in inherited forms 
of the disease [126, 127]. Familial NB accounts for 1-2% of newly diagnosed cases [128]. 
The expression of MYCN, a member of the MYC transcription factors family, is found in ~25% of 
NB cases. Immediately after its discovery in the 1980s, it has been confirmed to correlate with poor 
patient survival [129]. MYCN amplification is associated with a number of pro-tumorigenic processes 
that determine the development of high-risk NB, including increased metastatic activity, augmented 
angiogenesis, the inhibition of apoptosis and the stimulation of cell proliferation and pluripotency 
[129-131]. To date, MYCN amplification is a biomarker used for risk evaluation in NB patients. 
Disease prognosis and risk stratification are based on the following characteristics: age at diagnosis, 
localization of tumor, presence of metastases, histology of tumor, MYCN amplification, DNA ploidy, 
1p, 11q, and 17q chromosomal aberrations [120, 124, 125].  
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Treatment depends on the stage of the disease and includes all the existing modalities of modern 
cancer management (i.e., surgery, radiation therapy, chemotherapy and immunotherapy). 
 
The chemokine receptor repertoire of NB is poorly described. There is evidence that CXCR4 
expressed by tumor cells promotes non-invasive tumor growth being stimulated by CXCL12 
produced within the tumor microenvironment [132]. Airoldi et al. demonstrated that CXCR5+ NB 
cells migrate to the bone marrow in response to CXCL13 synthesis [133]. Additionally, it has been 
demonstrated that MYCN non-amplified high risk NB tumors can release CCL2, and by doing so 
attract iNKT cells that kill monocytes involved in tumor elimination processes [134].   
Figure 5. Clinical presentations of neuroblastoma. NB can arise anywhere along the sympathetic nervous 
system. The most common sites are the adrenal medulla, abdominal sympathetic ganglia, and mediastinum. 
Primary tumors in the neck or upper chest can cause Horner's syndrome (ptosis, miosis, and anhidrosis). 
Tumors along the spinal column can cause cord compression, with resulting paralysis. Higher-stage tumors 
often infiltrate local organ structures, surround critical nerves and vessels such as the celiac axis. NB typically 
metastasize to regional lymph nodes and to the bone marrow. NB also can metastasize to the liver.  
Illustration used with permission, copyright 2010 by Massachusetts Medical Society [125]. 
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3.5  Hepatic clearance of danger signals 
The elimination of pathogens and substances produced by damaged cells from the circulation is the 
essential function of the liver. In order to prevent the unnecessary activation of the entire immune 
system, the evolution of the liver has developed the capability for the local immune response and the 
elimination of pathogens. The initiation of innate immune response in the liver is dependent on 
various subsets of PRRs expressed on the liver-resident immune cells including macrophages 
(Kupffer cells), hepatic dendritic cells, neutrophils, NK cells and regulatory T cells [135, 136]. 
Liver sinusoidal endothelial cells (LSECs) are a notable type of liver cells forming the border between 
the blood and hepatocytes. The main feature of these cells is the formation of fenestrae, multiple pores 
which provide the opportunity for LSECs to literally filtrate the blood. LSECs are essential cells of 
liver metabolism. Through fenestrae, they uptake different substances, such as plasma proteins, 
albumin and lipoproteins [137]. The high endocytic potential of LSECs makes them a very important 
class of scavenger cells that eliminate the danger signals of both host and non-host origin. The 
permanent exposure of LSECs to various pathogens determine their involvement in immunity. There 
are many receptors known to be present on the surface of LSECs (e.g. TLRs, NLRs, RLRs) therefore 
these cells play a crucial role in antigen-presenting mechanisms and immune response activation 
[138]. LSECs contain a set of scavenger receptors (SR-A, SR-B, Stabilin-1 (SR-H1) and Stabilin-2 
(SR-H2)) which allow these cells to internalize and eliminate a tremendous number of foreign 
substances from the blood [136, 137]. Importantly, it has been demonstrated that fluorescein-













4. Aims of the thesis   
The specific aims of this thesis were: 
 To study the role of FPR1 in NB development and progression 
 To assess the significance of the CMKLR1/chemerin axis in NB tumorigenesis 
 To study the function of FPR1 in the liver-mediated clearance of formylated peptides from 
the circulation 
 To reveal the difference in the liver uptake of intravenously injected N-formyl peptide 




















5. Summary of papers 
Paper I 
Title: The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis. 
In this paper, we studied the role of FPR1, a G protein-coupled receptor with pattern recognition 
properties in NB tumorigenesis. FPR1 is involved in a broad range of host defense mechanisms and 
a variety of host-derived agonists of FPR1 have been identified, including formyl peptides released 
from the disrupted mitochondria of necrotic cells. We demonstrated the expression of FPR1 in seven 
different neuroblastoma cell lines and in primary tumors. Furthermore, FPR1 is expressed at increased 
levels in high stage tumors. The addition of the FPR1 agonist N-formyl-L-methionyl-L-leucyl-L-
phenylalanine (fMLP) to neuroblastoma cells in vitro caused an increase of intracellular calcium 
response and the activation of Akt, p38 and MAPK/ERK signal transduction pathways. All these 
signal transduction events were abrogated by the use of Cyclosporin H, a specific FPR1 antagonist. 
To assess the significance of this receptor in vivo, a set of neuroblastoma cell clones with different 
expression levels of FPR1 was generated. Xenograft models showed that cells with an overexpression 
of the receptor developed tumors significantly faster compared to the control group. Results obtained 
in this paper suggest that FPR1 may play a significant role in neuroblastoma tumorigenesis, and that 




Title: CMKLR1/chemerin axis in the neuroblastoma microenvironment. 
In Paper II, we investigated the impact of chemerin receptor CMKLR1 signaling on NB progression. 
Chemerin is an adipokine and immunomodulating factor that promotes the chemotaxis of immature 
DCs, NK cells, macrophages and endothelial cells. Secreted as prochemerin with low activity, it can 
be C-terminally processed by different proteases expressed by a broad range of cell types and tissues. 
The resulting isoforms vary in receptor affinity and biological activity and are natural ligands for the 
G protein-coupled receptors (GPCRs) CMKLR1, GPR1 and CCRL2. To date, the activation of 
CMKLR1 (Chemokine-like receptor 1) by chemerin and its role in metabolism and metabolic 
disorders as well as inflammation is best understood.  
The screening of microarray databases and the analysis of NB expression data showed a correlation 
between a high CMKLR1, GPR1 and CCRL2 expression and a reduction in the overall survival 
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probability. The expression of CMKLR1, GPR1, and chemerin was detected in nine NB cell lines 
using RT-PCR, Western blots and immunocytochemistry. Furthermore, chemerin and CMKLR1 
were detected in NB tumor tissue by immunofluorescence and immunoperoxidase staining. The 
stimulation of NB cell lines with active chemerin induces calcium mobilization and an increased 
phosphorylation of MEK1/2 and ERK1/2, thereby indicating an activation of the MAPK pathway. 
Morover, chemerin stimulation leads to increased NF-κB phosphorylation and translocation to the 
nucleus. The induction of NF-κB mediated signaling was observed by luciferase reporter assay. 
Serum, TNFα and IL-1β increased chemerin protein expression and secretion in NB. α-NETA, a 
small-molecule CMKLR1 inhibitor reduces the clonogenic potential of NB cells in vitro and hampers 
tumor growth in an animal model. Pharmacological interventions that target CMKLR1/chemerin 
signaling pathway may become an important adjuvant therapy for children with NB but further 
preclinical in vivo studies are warranted. 
 
Paper III 
Title: FITC Conjugation Markedly Enhances Hepatic Clearance of N-Formyl Peptides. 
In paper III, we demonstrated that the conjugation of an N-formyl peptide N-Formyl-Nle-Leu-Phe-
Nle-Tyr-Lys (fNLPNTL) with FITC significantly increases its uptake in the liver compared to native 
fNLPNTL. Along with that, we showed that the liver neutralizes circulating N-formyl peptides thus 
preventing the generalization of inflammation. In this study, anatomical distribution was evaluated 
by the intravenous injections of FITC-conjugated fNLPNTL and fNLPNTL, both labeled with 125I. 
The expression of FPR1 was revealed by PCR, WB and immunohistochemistry in both human and 
murine hepatocytes and LSECs, the unique subsets of liver cells that are capable of removing 
dangerous substances from the blood. Competitive studies in vitro showed that FITC-labeled FPR1 
agonist fNLPNTL is taken up in LSECs via both FPR1 and a scavenger receptor. In turn, hepatocytes 
bind FITC-fNLPNTL and fNLPNTL indistinguishably via FPR1. In this work, we proved that the 
chromogen conjugation of intravenously injected substances might transform them into ligands for 
scavenger receptors of the liver. Additionally, we have expanded the knowledge about the role of the 






6. Results and discussion 
It has been proven that functions of various components of the immune system are not limited to 
merely the recognition of pathogens. In this thesis, the role of two “inflammatory” receptors FPR1 
and CMKLR1 in NB development and progression is described. 
Additionally, this work provides two novel findings in the field of liver immunity. 
1. FPR1 expressed by liver cells actively removes circulating formyl peptides that might cause 
systemic inflammatory response syndrome. 
2. Fluorescein-labeled molecules are actively taken up from the blood by scavenger receptors of 
LSECs. Therefore, complicated liver physiology should be taken into account when planning 
research using the intravenous administration of chromogen-conjugated substances. 
 
6.1  Activation of FPR1 and CMKLR1 induces pro-carcinogenic pathways in NB 
in vitro 
FPR1 has previously been described to not only serve as a PRR, but to also participate in a plethora 
of biological events (Figure 6). Recently, its involvement in carcinogenesis has drawn researchers’ 
attention. Interestingly, the impact of FPR1 on tumor formation seems to be tissue- and organ-
specific. The majority of available publications suggest the pro-tumorigenic properties of FPR1 and 
a negative prognostic significance of highly-expressed FPR1 in tumor tissue [56, 85, 87, 88, 92, 140-
143]. However, Prevete and co-authors suggested tumor suppressor functions of FPR1 in gastric 
cancer [84]. Moreover, a work by E. Vacchelli, Y. Ma et al. reported that FPR1 is necessary for the 
formation of chemotherapy-induced antitumor immunity [91]. Notably, some studies do not 
distinguish between FPR1 expressed by tumor cells and the receptor residing on the surface of other 
cells of the tumor microenvironment; consequently discrepancies in the interpretation of the results 









In turn, CMKLR1 is expressed by iDCs, macrophages, endothelial cells and NKs, with its main 
function to recruit immune cells to the site of inflammation in response to the release of chemerin 
[145]. Besides the immunological functions, chemerin is an essential regulator of adipogenesis, hence 
contributing to the development of obesity and diabetes type 2 [115, 146].  Additionally, CMKLR1-
chemerin interaction has been shown in various conditions, including psoriasis, preeclampsia, 
atherosclerosis, renal diseases, etc. The functional activity of CMKLR1 is dependent on the cleaved 
form of chemerin (described in Introduction 3.3.2) (Figure 7) [112, 113, 147-149].  
The data from the literature describing the role of CMKLR1 in cancer are very limited. Most papers 
focus on the plasma levels of chemerin, and do not pay attention to the expression and functions of 
the receptor. [111] 
 
Figure 6. FPRs in humans. In humans, three FPRs are known. These receptors have been described in myeloid 
cells and later in various tissues and cell types. Depending on the ligand and site of expression, FPRs can initiate 
different processes. 





In our work we aimed to establish whether FPR1 (Paper I) and CMKLR1 (Paper II) activation 
influences NB tumorigenesis. As the initial point for these studies, we screened publicly available 
expression datasets [150], and found that NB patients with tumors expressing high levels of the 
receptors have a significantly lower survival probability. In vitro, we tested seven (Paper I) and 10 
(Paper II) NB cell lines, and 27 tumor samples and showed abundant expression of both receptors in 
all specimens. Using specific agonists, we demonstrated that stimulation of the receptors lead to the 
enhanced release of Ca2+ from intracellular stores and the activation of various signaling pathways 
including MAPK/ERK, Akt and P38-MAPK for FPR1 and MAPK/ERK, and NF-κB for CMKLR1. 
ERK1 and ERK2 are extracellular signal-regulated kinases, members of the family of mitogen-
activated protein kinases, transferring diverse extracellular signals to a cell’s interior. The active 
forms of these kinases are detected in approximately one-third of all cancers [151].  Currently, more 
than 160 ERK 1/2 targets regulating cell growth, motility, survival, differentiation and metabolism 
have been identified [152]. The main mechanism of ERK 1/2-mediated tumorigenesis is the 
prevention of apoptosis via the inhibition of BCL-2/MCL-1 complex [153]. 
Figure 7. Functions of chemerin and CMKLR1. Depending on the cleavage site, chemerin might be involved in a 
variety of functions in inflammation, skin, obesity, and cell differentiation. 




The PI3K/Akt/mTOR pathway has been shown to play an important role in the development and 
progression of NB [154]. Being activated, Akt regulates many oncogenic signaling pathways 
associated with tumor growth and survival [155]. In NB setting, it has been demonstrated that 
phosphorylated Akt has a negative prognostic value [156].  
NF-κB is a complex proinflammatory transcription factor that comprehensively controls cell survival 
and the production of cytokines [157]. According to previous studies, its active form is required for 
the progression and drug resistance of high-risk NB [158]  
Intracellular Ca2+ is one of the main drivers and regulators of cell migration, and its liberation by 
GPCRs activation is one of the primary regulatory pathways in cytoplasmic Ca2+ balance [159]. 
Tumor cells can alter Ca2+ signaling in order to increase proliferation and metastatic capability [160]. 
TNFα and IL-1 are inflammatory cytokines that share many biological properties and often work 
cooperatively in order to maintain inflammation [161, 162]. In paper II, we discovered that TNFα and 
IL-1β increase the liberation of chemerin by NB cells and tumor microenvironment. Thus, NB-
associated inflammation contributes to tumor progression via chemerin-CMKLR1 interaction. 
Taken together, our in vitro data from Paper I and Paper II indicate that the inflammatory receptors 
FPR1 and CMKLR1 are functionally expressed by NB cells. Being stimulated by selective agonists, 
these receptors trigger a variety of cellular responses attributed to augmented tumorigenicity. 
Speaking of the source of stimulatory signals for the receptors, we assume that formylated peptides 
are released from the mitochondria of necrotic tumor cells, while chemerin is produced by NB cells 
or other cells within the tumor microenvironment. 
 
6.2  High expression of FPR1 significantly enhances NB tumorigenesis in vivo 
In Paper I, in order to confirm our hypothesis in vivo, we carried out a xenograft experiment using 
immunodeficient NMRI nu/nu mice. Despite the growing body of publications on different aspects 
of FPR1 biology, there are a very limited number of published studies using animal models. Zhou 
and co-authors in 2005, and Yang and co-authors in 2011, demonstrated that glioblastoma U-87 cells 
with a siRNA knockdown of FPR1 formed tumors more slowly than control cells, and animals with 
wild-type cells had died or had to be sacrificed significantly earlier than animals with depleted FPR1 
[56, 163].  In contrast, Prevete et al. discovered that shRNA silencing of FPR1 in gastric cancer AGS 
and MKN45 cell lines led to an accelerated tumor development [84]. They hypothesized that in gastric 
cancer, FPR1 is a strong inhibitor of angiogenesis; therefore, its silencing induces neovascularization, 
which results in enhanced tumor growth. 
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In our work, in addition to the knockdown FPR1 construct, we developed a cell clone with an 
overexpression of the receptor. The use of doxycycline-inducible constructs allowed us to maintain 
the constant level of the receptor expression during the entire experiment. We observed that animals 
injected with NB cells with an increased expression of FPR1 developed tumors and reached a humane 
endpoint significantly faster compared with other experimental groups. As a result, we demonstrated 
for the first time that FPR1 augments NB tumorigenesis in experimental animal models. 
 
6.3 A small-molecule CMKLR1 inhibitor α-NETA diminishes the clonogenicity of 
NB cells in vitro and tumor growth in vivo 
2-(α-naphthoyl) ethyltrimethylammonium iodide (α-NETA) has been described in the 1980s as a 
selective inhibitor of choline acetyltransferase, the enzyme responsible for the biosynthesis of the 
neurotransmitter acetylcholine [164, 165]. Recently, α-NETA has been demonstrated to be a potent 
CMKLR1 antagonist that inhibits the β-arrestin 2 association with CMKLR1 upon chemerin 
stimulation and decreases chemerin-driven cell migration [166]. 
In Paper II, we were able to show that the incubation of NB cells with α-NETA reduces proliferation 
activity and clonogenicity. In order to study the possible effects of CMKLR1 inhibition on NB in 
vivo, we established subcutaneous xenograft tumor model. Animals were divided randomly into three 
groups: the pre-treatment group, animals receiving s.c. α-NETA injections daily beginning 24 hours 
after xenografting; the treatment group, animals receiving s.c. α-NETA injections daily when a tumor 
reached a volume of ≥ 0.15 ml; and the control group, animals receiving vehicle injections. In this 
experiment, we observed no difference in tumor growth and animals’ survival between treatment and 
control groups, although for the pre-treatment group the delay in tumor formation was statistically 
significant. Hence, CMKLR1 might exert its tumor promoting effect during the initial steps of NB 
development, so the blocking of the receptor could represent a therapy option for the treatment of 
NB. 
 
6.4  Liver is responsible for the removal of formyl peptides from circulation 
The liver collects blood from all the organs in the human body, and constantly encounters pathogens 
and host-released alarmins. Hence, the liver has evolutionary become a major immune organ, broadly 
involved in both the innate and adaptive immune response [135, 167]. The involvement of the liver 
in innate immunity is dependent on the broad network of PRRs and scavenger receptors expressed on 
the surface of hepatocytes and LSECs [137]. 
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Mitochondria-derived formylated peptides released upon massive injury initiate a systemic 
inflammatory response similar to bacteria-induced inflammation. This could lead to systemic 
inflammatory response syndrome (SIRS), thus resulting in sepsis [168, 169]. 
To the best of our knowledge, we found for the first time in Paper III that formyl peptides are actively 
taken up from the circulatory system by LSECs expressing FPR1. In this work, we revealed that FPR1 
is present in the liver cells in both humans and mice, and the incubation of the cells with a FITC-
labeled formylated peptide resulting in the internalization of the peptide. In vivo experiments, in 
which we intravenously injected radioactive-labeled formylated peptide into mice, confirmed our in 
vitro data.  
Interestingly, in analyzing the results of animal experiments, we observed significant differences in 
the uptake between FITC-labeled and unconjugated peptide. We confirmed this finding in vitro by 
the preincubation of LSECs and hepatocytes with unlabeled peptide prior to incubation with a FITC-
labeled counterpart. As a result, we could not observe the fluorescence in hepatocytes because the 
original peptide competitively bound all active FPRs. While we observed the fluorescence in LSECs, 
suggesting that the FITC group converts the protein into a ligand for scavenger receptors apart from 
FPR1. This raises a fundamental concern on the validity of experiments utilizing significantly 















7. Concluding remarks 
Despite the recent scientific breakthroughs and modern advances in therapy, NB remains one of the 
most unfavorable pediatric cancers. There is a great need for novel prognostic factors and, drug targets 
in particular. In this thesis, the signaling pathways of the inflammatory receptors FPR1 and CMKLR1 
have been studied in terms of their contribution to NB tumorigenesis. We were able to demonstrate 
that both receptors participate in tumor progression and the development of a highly malignant 
phenotype. Our experimental results supported by survival data obtained from several cohorts may 
provide a foundation for future research aimed at specifically targeting of FPR1 and CMKLR1 in 
NB. Moreover, drugs selectively targeting these receptors could be a novel approach in the treatment 
of patients with NB. 
Additionaly, this thesis expands the knowledge of FPR1 biology, hence revealing the receptor’s 
expression in the liver and identifying its role in hepatic clearance. 
Hopefully, the data on the scavenging of fluorescent substances by the liver will help the research 
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